Icon Plc (NASDAQ:ICLR) – Research analysts at KeyCorp increased their Q4 2017 earnings per share estimates for shares of Icon Plc in a research report issued on Sunday, Zacks Investment Research reports. KeyCorp analyst D. Hooker now anticipates that the medical research company will post earnings per share of $1.41 for the quarter, up from their prior estimate of $1.40. KeyCorp has a “Overweight” rating and a $125.00 price objective on the stock. KeyCorp also issued estimates for Icon Plc’s Q1 2018 earnings at $1.42 EPS, Q2 2018 earnings at $1.47 EPS, Q3 2018 earnings at $1.52 EPS, Q4 2018 earnings at $1.56 EPS, FY2018 earnings at $5.97 EPS and FY2019 earnings at $5.89 EPS.
Icon Plc (NASDAQ:ICLR) last released its earnings results on Thursday, October 26th. The medical research company reported $1.35 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.32 by $0.03. The business had revenue of $440.30 million for the quarter, compared to analyst estimates of $438.09 million. Icon Plc had a return on equity of 28.42% and a net margin of 16.37%. The company’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.19 earnings per share. WARNING: “KeyCorp Analysts Lift Earnings Estimates for Icon Plc (ICLR)” was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://stocknewstimes.com/2017/11/24/q4-2017-earnings-forecast-for-icon-plc-iclr-issued-by-keycorp.html.
Other research analysts have also issued research reports about the company. SunTrust Banks, Inc. raised Icon Plc from a “hold” rating to a “buy” rating and boosted their target price for the company from $93.00 to $126.00 in a report on Monday, July 31st. Jefferies Group LLC reissued a “buy” rating on shares of Icon Plc in a report on Sunday, July 30th. Credit Suisse Group reissued a “buy” rating on shares of Icon Plc in a report on Friday, July 28th. Zacks Investment Research raised Icon Plc from a “hold” rating to a “buy” rating and set a $120.00 target price on the stock in a report on Thursday, August 24th. Finally, ValuEngine raised Icon Plc from a “hold” rating to a “buy” rating in a report on Friday, September 1st. Four research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Icon Plc has a consensus rating of “Buy” and an average price target of $121.00.
Icon Plc (NASDAQ:ICLR) opened at $118.35 on Tuesday. The stock has a market capitalization of $6,408.89, a P/E ratio of 22.72, a PEG ratio of 1.83 and a beta of 0.56. The company has a quick ratio of 1.90, a current ratio of 1.90 and a debt-to-equity ratio of 0.31. Icon Plc has a twelve month low of $73.76 and a twelve month high of $124.48.
A number of hedge funds have recently made changes to their positions in the stock. Fieldpoint Private Securities LLC acquired a new position in Icon Plc during the third quarter worth $330,000. Insight Capital Research & Management Inc. acquired a new position in Icon Plc during the third quarter worth $1,359,000. Janney Montgomery Scott LLC grew its holdings in Icon Plc by 11.1% during the third quarter. Janney Montgomery Scott LLC now owns 12,237 shares of the medical research company’s stock worth $1,394,000 after acquiring an additional 1,222 shares during the period. Cubist Systematic Strategies LLC grew its holdings in Icon Plc by 92.8% during the third quarter. Cubist Systematic Strategies LLC now owns 9,339 shares of the medical research company’s stock worth $1,064,000 after acquiring an additional 4,495 shares during the period. Finally, Vident Investment Advisory LLC grew its holdings in Icon Plc by 248.8% during the third quarter. Vident Investment Advisory LLC now owns 35,263 shares of the medical research company’s stock worth $4,016,000 after acquiring an additional 25,152 shares during the period. 89.75% of the stock is currently owned by hedge funds and other institutional investors.
Icon Plc Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with MarketBeat.com's FREE daily email newsletter.